Asymchem Laboratories (Tianjin) Co., Ltd. (HKG: 6821)

Market Cap	28.60B
Revenue (ttm)	6.17B
Net Income (ttm)	851.80M
Shares Out	n/a
EPS (ttm)	2.39
PE Ratio	33.58
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	183,800
Open	50.80
Previous Close	51.90
Day's Range	50.50 - 52.70
52-Week Range	37.60 - 93.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 28, 2025

About Asymchem Laboratories (Tianjin)

Asymchem Laboratories (Tianjin) Co., Ltd. provides clinical stage CDMO, commercial stage CDMO, and emerging services in Mainland China and internationally. The company offers process development and optimization, analytical services, and scale-up services for small molecule drug products throughout the pre-clinical and clinical stage; and ton-scale manufacturing services for registered starting materials, advanced intermediates, and active pharmaceutical ingredients. It also engages in pre-formulation and formulation development; chemical macro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 9,788
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6821

Financial Performance

In 2023, Asymchem Laboratories (Tianjin)'s revenue was 7.83 billion, a decrease of -23.70% compared to the previous year's 10.26 billion. Earnings were 2.27 billion, a decrease of -31.28%.

Financial numbers in CNY